Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Miltefosine for Mucosal Leishmaniasis

This study has been completed.
Sponsor:
Information provided by:
AB Foundation
ClinicalTrials.gov Identifier:
NCT00373776
First received: September 7, 2006
Last updated: NA
Last verified: September 2006
History: No changes posted

September 7, 2006
September 7, 2006
April 2004
Not Provided
Efficacy
Same as current
No Changes Posted
toxicity
Same as current
Not Provided
Not Provided
 
Miltefosine for Mucosal Leishmaniasis
Not Provided

This trial will study miltefosine as a treatment for mucosal leishmaniasis.

Treat bolivian mucosal leishmaniasis with miltefosine.

Interventional
Phase 1
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Leishmaniasis
Drug: miltefosine 2.5 mg/kg/day for 28 days
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
75
May 2006
Not Provided

Inclusion Criteria:

  • Mucosal leishmaniasis

Exclusion Criteria:

  • Abnormal liver function tests (LFT)
  • Abnormal kidney function test
  • Concomitant diseases
Both
12 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Bolivia
 
NCT00373776
04--01
Not Provided
Not Provided
AB Foundation
Not Provided
Principal Investigator: Jaime soto, MD CIBIC
AB Foundation
September 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP